Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers January 30, 2015
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - January 30, 2015

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

1/30/15 - Alimera Sciences' ILUVIEN Achieves Marketing Authorization in Finland and Luxembourg [Manufacturing Close - Up]
Alimera Sciences reported that marketing authorization has been granted by the Finnish Medicines Agency in Finland and the Ministry of Health in Luxembourg to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema considered insufficiently responsive to available therapies. ILUVIEN is now approved for...
1/30/15 - Amgen Files Applications in the US and Europe for Kyprolis (carfilzomib) for the Treatment of Relapsed Multiple Myeloma [Professional Services Close - Up]
Amgen and its subsidiary Onyx Pharmaceuticals reported the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration and a Marketing Authorization Application to the European Medicines Agency for Kyprolis for Injection to seek approval for the treatment of patients with relapsed multiple myeloma who have received at
1/30/15 - AMITIZA(R) (lubiprostone) Mutual Recognition Procedure Closes With Recommendation for Approval in European Countries
Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, today announced the successful completion of the European Mutual Recognition Procedure for AMITIZA for the treatment of chronic idiopathic constipation in select European countries, resulting in a recommendation for marketing authorization. Based on the approval in the United..
1/30/15 - Astellas Pharma and Immunomic Therapeutics Announce Exclusive License for JRC2-LAMP-vax, a Vaccine for Japanese Red Cedar Pollinosis
HERSHEY, Pa., Rockville, Md. and TOKYO, Jan. 29, 2015/ PRNewswire/ Immunomic Therapeutics, Inc., a company developing next-generation vaccines based on the LAMP-vax platform, and Astellas Pharma Inc. today announced they have entered into an exclusive license agreement for Japan to develop and commercialize JRC2-LAMP-vax, Immunomic Therapeutics'
1/30/15 - AstraZeneca's genetic scissors to refine drugs
UK DRUG giant AstraZeneca said yesterday it has struck four research agreements in the hot area of genome editing as it bets on a new "genetic scissors" technology to deliver better and more precise drugs for a range of diseases. The deals will allow AstraZeneca to use its so-called CRISPR technology, which stands for clustered regularly interspace
1/30/15 - Dendreon Reaches Agreement for Valeant to Serve as Stalking Horse Bidder in Court-Supervised Sales Process
January 29, 2015 Dendreon Corporation announced today that it has reached an agreement with Valeant Pharmaceuticals International, Inc. pursuant to which, subject to bankruptcy court approval, Valeant will serve as the stalking horse bidder in conjunction with a court-supervised sales process. The Company also announced that it would be ext
1/30/15 - Doosan Babcock's 25m Angus contract for GSK Active Pharmaceutical Ingredients plant in Montrose [Saudi Press Agency (Saudi Arabia)]
The investment in the new Active Pharmaceutical Ingredients plant was first announced in November 2013 during a meeting between Finance Secretary John Swinney and Roger Connor, GSK's president of global manufacturing and supply. GSK's existing Montrose operation, which was seen as being under threat of closure just a few years ago, produces medicin
1/30/15 - Dr. Jeffrey H. Lawson to Keynote at the International Symposium for Endovascular Therapy [Professional Services Close - Up]
Jeffrey H. Lawson, M.D., Ph.D., Vice Chair for Research, Professor of Surgery and Pathology at Duke University Medical Center, Director of the Vascular Research Laboratory, Director of Clinical Trials for the Department of Surgery and clinical consultant to Humacyte, is the keynote speaker at the 27th International Symposium on Endovascular Therapy
1/30/15 - Findings from Bar-Ilan University Provides New Data on Enzymes and Coenzymes (Application of EMBM to Structure-Based Design of Warheads for Protease...
According to news reporting out of Ramat Gan, Israel, by NewsRx editors, research stated, "Most CADD tools handle non-covalent enzyme inhibitors, despite the growing interest of the pharma industry in covalent inhibitors." Our news journalists report that additional information may be obtained by contacting T. Traube, Bar Ilan University, Dept. of
1/30/15 - Findings from C. Gege and Co-Researchers Provides New Data on Medicinal Chemistry (Knocking on FXR's door: the "hammerhead"-structure series of FXR...
By a News Reporter-Staff News Editor at Health& Medicine Week Fresh data on Health and Medicine are presented in a new report. According to news originating from Heidelberg, Germany, by NewsRx correspondents, research stated, "The Farnesoid X Receptor was recently validated in clinical studies using the bile acid analogue Obeticholic Acid as an a
1/30/15 - GNW-News: Santhera Extends Executive Management and Appoints Chief Commercial Officer (english)
Santhera Extends Executive Management and Appoints Chief Commercial Officer Santhera Pharmaceuticals Holding AG/ Santhera Extends Executive Management and Appoints Chief Commercial Officer. Liestal, Switzerland, January 30, 2015- Santhera Pharmaceuticals today announced the strengthening of the leadership team through nomination of senior...
1/30/15 - Have we become too dependent on medication? [Yerepouni Daily News (Armenia)]
A 2010 survey from The Henry J. Kaiser Family Foundation revealed that between 1999 and 2009, the number of prescriptions dispensed in the US increased by 39%, from 2.8 billion to 3.9 billion. A 2014 survey from the Centers for Disease Control and Prevention revealed 48% of us have used at least one prescription drug in the past 30 days- 5% more th
1/30/15 - Ireland : ACTAVIS PHARMACEUTICALS buys AUDEN MCKENZIE for 306m, following major acquisitions [TendersInfo (India)]
Ireland- based Actavis Pharmaceuticals has acquired generic drug maker Auden Mckenzie in a deal worth 306 m. Before it announced the Allergan deal in November, the company acquired rival Forest Laboratories for $25 bn in February and infectious disease expert Durata for $675 m in October. Actavis said the acquisition of Auden Mckenzie will make i
1/30/15 - Johnson & Johnson: U.S. FDA Approves IMBRUVICA (ibrutinib) for the Treatment of Waldenstrom's Macroglobulinemia: First FDA-Approved Therapy for This Disease
Release date- 29012015- HORSHAM, PA- Janssen Biotech, Inc. today announced that the U.S. Food and Drug Administration has approved IMBRUVICA capsules as the first therapy indicated specifically for patients with Waldenstrom's macroglobulinemia, 1 a rare, indolent type of B-cell lymphoma. IMBRUVICA was granted Breakthrough Therapy Designation for WM
1/30/15 - NAFDAC Earns Global Accolade for Saving Lives
The United States Agency for International Development has presented the National Agency for Food and Drug Administration and Control Central Drug Control Laboratory a quality certificate for curbing the deaths caused by fake medicines. USAID's Director in Nigeria, Michael Harvey, presented the International Organization for Standardization...
1/30/15 - Novo Nordisk Secures FDA OK for Norditropin FlexPro 30 mg/3.0 mL for Patients with Growth Hormone Disorders [Manufacturing Close - Up]
Novo Nordisk reported the U.S. Food and Drug Administration approval of Norditropin FlexPro 30 mg/3. 0 mL, a prefilled injection pen for patients with growth hormone-related disorders. "Novo Nordisk is committed to advancing growth hormone delivery devices with patients in mind," said Eddie Williams, senior vice president, Biopharmaceuticals, Novo
1/30/15 - Octapharma USA Gets FDA Approval for 2nd Octagam 10 Percent Manufacturing Site [Professional Services Close - Up]
Octagam 10 percent for the U.S. market can now be manufactured at FDA- licensed facilities in both Stockholm, Sweden and Vienna. "The FDA approval of Octapharma's Vienna manufacturing site for Octagam 10 percent is great news for patients, as it will help facilitate product availability and enhances production flexibility," said Flemming Nielsen,
1/30/15 - Patented Medicine Prices Review Board Sets Public Hearing [Manufacturing Close - Up]
The Patented Medicine Prices Review Board will hold a public hearing in the matter of the price of the patented medicine Soliris, and Alexion Pharmaceuticals, the pharmaceutical company that holds the patent for Soliris and sells the medicine in Canada. According to a media release, further details on the public hearing and a case management confer
1/30/15 - Plaintiffs Level Allegations Against Maker of Prescription Drug Risperdal [Health & Beauty Close - Up]
Attorney Wendy R. Fleishman of the law firm Lieff Cabraser Heimann& Bernstein reported that four young men prescribed the antipsychotic medication Risperdal recently filed separate personal injury lawsuits alleging that Risperdal is a defective and dangerous prescription drug. According to a company release, the complaints were brought against...
1/30/15 - Product and Pipeline Analysis of the Antibacterial Drugs Market 2015
Dublin- Research and Markets has announced the addition of the "A Product and Pipeline Analysis of the Antibacterial Drugs Market" report to their offering. Drug-resistant bacteria, or superbugs, pose a serious threat to human health. Product and pipeline assessment for recently approved antibacterial drugs, antibacterials under FDA review, as well
1/30/15 - Research and Markets Offers Report: 4th Annual Pharma Pricing and Reimbursement Forum [Manufacturing Close - Up]
Research and Markets has reported the addition of the "4th Annual Pharma Pricing and Reimbursement Forum" conference to its offerings. In a release, Research and Markets noted that report highlights include:. Research and Markets is a source for international market research reports.
1/30/15 - Santhera Extends Executive Management and Appoints Chief Commercial Officer
Santhera Pharmaceuticals Holding AG/ Santhera Extends Executive Management and Appoints Chief Commercial Officer. Liestal, Switzerland, January 30, 2015- Santhera Pharmaceuticals today announced the strengthening of the leadership team through nomination of senior members of staff to its Executive Management and the appointment of a Chief...
1/30/15 - St. Jude Medical Updates on FDA Approval of FlexAbility Ablation Catheter [Health & Beauty Close - Up]
St. Jude Medical reported U.S. Food and Drug Administration approval of the FlexAbility Ablation Catheter, a new ablation technology used by electrophysiologists for the treatment of cardiac arrhythmias. Andrea Natale, executive medical director at the Texas Cardiac Arrhythmia Institute. "As we developed the FlexAbility ablation catheter, we worke
1/30/15 - Stifel Nicolaus Boosts Array Biopharma Price Target to $9.00 (ARRY) [Cihan News Agency (Turkey)]
Array Biopharma had its price objective raised by Stifel Nicolaus from $6.00 to $9.00 in a research report released on Monday morning. Analysts at Zacks downgraded shares of Array Biopharma from an outperform rating to a neutral rating and set a $5.20 price target on the stock in a research note on Tuesday, January 6th. Separately, analysts at Jeff
1/30/15 - Sweden,United States : FDA approves new strength of Norditropin FlexPro [TendersInfo (India)]
Novo Nordisk declared that the Food and Drug Administration has given green signal to a new 30 mg/3. 0 mL strength of Norditropin FlexPro pen. Norditropin FlexPro is indicated for growth failure in children due to inadequate endogenous GH secretion, children with short stature associated with Noonan or Turner syndrome, children with short stature b
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Drug Therapy Management Series Part I: Cardiovascular Disorders
This lesson is supported by:
RxSchool
Workplace Safety & Joint Commission Standards for Pharmacy Professionals
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415